Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT03476239 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab
DRUG: Dexamthasone

Sponsor

Amgen